Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies. At the APACC 2023 conference, Dr. Iskandar Azwa delivered an insightful presentation on "The Role of Nucleosides in Second-Line HIV Treatment." Our journal had the privilege to conduct an in-depth interview with Dr. Azwa regarding the choices for second and third-line treatment for HIV/AIDS patients.
Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies.